Molly H Thompson1, Sylvia H Wilson2, Brittany L Toussaint1, Cameron L Jordan1, Genevieve L Hayes1, Brian P McKinzie1, Bethany J Wolf3, Larry C Field4. 1. Department of Pharmacy Services, Medical University of South Carolina, 150 Ashley Avenue, MSC 584, Charleston, SC, 29425, USA. 2. Department of Anesthesia and Perioperative Medicine, Medical University of South Carolina, 167 Ashley Avenue, Suite 301, MSC 912, Charleston, SC, 29425-9120, USA. Electronic address: wilsosh@musc.edu. 3. Department of Public Health Sciences, Medical University of South Carolina, 135 Cannon St, Suite 303, MSC 835, Charleston, SC, 29425, USA. 4. Department of Anesthesia and Perioperative Medicine, Medical University of South Carolina, 167 Ashley Avenue, Suite 301, MSC 912, Charleston, SC, 29425-9120, USA.
Abstract
STUDY OBJECTIVE: Characterize the incidence of elevated aPTT results in patients treated with prophylactic, subcutaneous unfractionated heparin (UFH). DESIGN: Retrospective, cohort analysis. SETTING: Single-center, university hospital. MEASUREMENTS: Evaluation of 257 patients with activated partial thromboplastin time (aPTT) testing both prior to and following subcutaneous (SC) unfractionated heparin (UFH) therapy. MAIN RESULTS: Evaluated patients received UFH 5000 units every 8 hours. Baseline aPTT values were within the normal range (mean±SD, 32.0±8.5 seconds). After initiation of UFH, aPTT values increased (mean±SD, 37.6±15.2 seconds). After 24 hours of SC UFH, mean aPTT values (mean±SD, 38.6±15.5) exceeded the normal laboratory range (23.3-35.7 seconds). An elevated aPTT result after UFH was associated with baseline aPTT, length of therapy, and weight-based UFH dose. A significant association was not identified between aPTT elevation and age, race, sex, history of liver disease, type of admission, or transfusion of blood products. CONCLUSIONS: Treatment with UFH resulted in a small, but significant, increase in aPTT.
STUDY OBJECTIVE: Characterize the incidence of elevated aPTT results in patients treated with prophylactic, subcutaneous unfractionated heparin (UFH). DESIGN: Retrospective, cohort analysis. SETTING: Single-center, university hospital. MEASUREMENTS: Evaluation of 257 patients with activated partial thromboplastin time (aPTT) testing both prior to and following subcutaneous (SC) unfractionated heparin (UFH) therapy. MAIN RESULTS: Evaluated patients received UFH 5000 units every 8 hours. Baseline aPTT values were within the normal range (mean±SD, 32.0±8.5 seconds). After initiation of UFH, aPTT values increased (mean±SD, 37.6±15.2 seconds). After 24 hours of SC UFH, mean aPTT values (mean±SD, 38.6±15.5) exceeded the normal laboratory range (23.3-35.7 seconds). An elevated aPTT result after UFH was associated with baseline aPTT, length of therapy, and weight-based UFH dose. A significant association was not identified between aPTT elevation and age, race, sex, history of liver disease, type of admission, or transfusion of blood products. CONCLUSIONS: Treatment with UFH resulted in a small, but significant, increase in aPTT.
Authors: A Rodgers; N Walker; S Schug; A McKee; H Kehlet; A van Zundert; D Sage; M Futter; G Saville; T Clark; S MacMahon Journal: BMJ Date: 2000-12-16
Authors: Hervé Decousus; Victor F Tapson; Jean-François Bergmann; Beng H Chong; James B Froehlich; Ajay K Kakkar; Geno J Merli; Manuel Monreal; Mashio Nakamura; Ricardo Pavanello; Mario Pini; Franco Piovella; Frederick A Spencer; Alex C Spyropoulos; Alexander G G Turpie; Rainer B Zotz; Gordon Fitzgerald; Frederick A Anderson Journal: Chest Date: 2010-05-07 Impact factor: 9.410
Authors: Susan R Kahn; Wendy Lim; Andrew S Dunn; Mary Cushman; Francesco Dentali; Elie A Akl; Deborah J Cook; Alex A Balekian; Russell C Klein; Hoang Le; Sam Schulman; M Hassan Murad Journal: Chest Date: 2012-02 Impact factor: 9.410
Authors: Jennifer J Davis; Byron R Bankhead; Erik J Eckman; Austin Wallace; Joseph Strunk Journal: Reg Anesth Pain Med Date: 2012 Nov-Dec Impact factor: 6.288
Authors: Boyd A Swinburn; Gary Sacks; Kevin D Hall; Klim McPherson; Diane T Finegood; Marjory L Moodie; Steven L Gortmaker Journal: Lancet Date: 2011-08-27 Impact factor: 79.321
Authors: John A Heit; W Michael O'Fallon; Tanya M Petterson; Christine M Lohse; Marc D Silverstein; David N Mohr; L Joseph Melton Journal: Arch Intern Med Date: 2002-06-10
Authors: Terese T Horlocker; Denise J Wedel; John C Rowlingson; F Kayser Enneking; Sandra L Kopp; Honorio T Benzon; David L Brown; John A Heit; Michael F Mulroy; Richard W Rosenquist; Michael Tryba; Chun-Su Yuan Journal: Reg Anesth Pain Med Date: 2010 Jan-Feb Impact factor: 6.288